Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Graefe's Archive for Clinical and Experimental Ophthalmology
Published in: Graefe's Archive for Clinical and Experimental Ophthalmology 6/2006

01-06-2006 | Clinical Investigation

Intraocular lymphoma 2000–2005: results of a retrospective multicentre trial

Authors: Kristoph Jahnke, Agnieszka Korfel, Julia Komm, Nikolaos E. Bechrakis, Harald Stein, Eckhard Thiel, Sarah E. Coupland

Published in: Graefe's Archive for Clinical and Experimental Ophthalmology | Issue 6/2006

Login to get access

Abstract

Background

The prognosis of intraocular lymphoma (IOL) is poor, and the optimal treatment has yet to be defined. This study assesses the clinical characteristics and outcome of patients with IOL diagnosed and treated in the new millennium.

Methods

Patient data in this retrospective multicentre study were compiled by standardised questionnaires sent to seven university ophthalmology departments. All cases diagnosed with primary and secondary IOL in the past 5 years not associated with HIV infection were included.

Results

Twenty-two patients, 11 men and women; median age 64 (range 38–83) years, median Karnofsky performance status 90% (range 50–100%), were included. Nineteen patients had primary IOL (PIOL): 13 a newly diagnosed disease and six an ocular relapse of primary central nervous system lymphoma (PCNSL). Three patients had secondary IOL. First-line treatment for IOL included systemic chemotherapy in 13 cases, ocular radiation in six and intraocular chemotherapy in three. Complete remission was achieved in 14/20 evaluable patients, partial remission in five and stable disease in one. All patients treated with ifosfamide (IFO) or trofosfamide (TRO) (n=8) responded. Median progression-free survival (PFS) and overall survival were 10 (range 1+ to 44.5+) and 22.5 (range 1+ to 49+) months, respectively. Patients with newly diagnosed PIOL and ocular relapse of PCNSL had a median PFS of 10 (range 1+ to 44.5+) and 6 (range 2 to 6+) months, respectively. Median PFS was 12 (range 3+ to 22.5+) months after systemic and 5.5 (range 1+ to 44.5+) months after local first-line therapy.

Conclusions

The prognosis of PIOL is similar to that of PCNSL without ocular involvement. Systemic therapy possibly prolongs PFS as compared with local management of (P)IOL. The high response rate to monotherapy with IFO and TRO is promising.
Literature
1.
Akpek EK, Ahmed I, Hochberg FH, Soheilian M, Dryja TP, Jakobiec FA, Foster CS (1999) Intraocular-central nervous system lymphoma. Clinical features, diagnosis and outcome. Ophthamology 106:1805–1810CrossRef
2.
Barr CC, Green WR, Payne JW, Knox DL, Jensen AD, Thompson RL (1975) Intraocular reticulum-cell sarcoma: clinicopathologic study of four cases and review of the literature. Surv Ophthalmol 19:224–239PubMed
3.
Batchelor TT, Kolak G, Ciordia R, Foster CS, Henson JW (2003) High-dose methotrexate for intraocular lymphoma. Clin Cancer Res 9:711–715PubMed
4.
Blay JY, Conroy T, Chevreau C, Thyss A, Quesnel N, Eghbali H, Bouabdallah R, Coiffier B, Wagner JP, Le Mevel A, Dramais-Marcel D, Baumelou E, Chauvin F, Biron P (1998) High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series. J Clin Oncol 16:864–871PubMed
5.
Buggage RR, Chan CC, Nussenblatt RB (2001) Ocular manifestations of central nervous system lymphoma. Curr Opin Oncol 13:137–142CrossRefPubMed
6.
Cassoux N, Merle-Beral H, Leblond V, Bodaghi B, Milea D, Gerber S, Fardeau C, Reux I, Xuan KH, Chan CC, LeHoang P (2000) Ocular and central nervous system lymphoma: clinical features and diagnosis. Ocul Immunol Inflamm 8:243–250CrossRefPubMed
7.
Char DH, Ljung BM, Miller T, Phillips T (1988) Primary intraocular lymphoma (ocular reticulum cell sarcoma) diagnosis and management. Ophthalmology 95:625–630PubMed
8.
Coupland SE, Bechrakis NE, Anastassiou G, Foerster A, Heiligenhaus A, Pleyer U, Hummel M, Stein H (2003) Evaluation of vitrectomy specimens and chorioretinal biopsies in the diagnostic of primary intraocular lymphoma in patients with Masquerade syndrome. Graefe Arch Clin Exp Ophthalmol 241:860–870CrossRef
9.
Coupland SE, Heimann H, Bechrakis NE (2004) Primary intraocular lymphoma: a review of the clinical, histopathological and molecular biological features. Graefe Arch Clin Exp Ophthalmol 242:901–913CrossRef
10.
Coupland SE, Hummel M, Stein H, Willerding G, Jahnke K, Stoltenburg-Didinger G (2005) Demonstration of identical clonal derivation in a case of “oculocerebral” lymphoma. Br J Ophthalmol 89:238–239CrossRefPubMed
11.
12.
DeAngelis LM, Hormigo A (2004) Treatment of primary central nervous system lymphoma. Semin Oncol 31:684–692PubMedCrossRef
13.
Eby NL, Grufferman S, Flannelly CM, Schold SC Jr, Vogel FS, Burger PC (1988) Increasing incidence of primary brain lymphoma in the U.S. Cancer 62:2641–2665CrossRef
14.
Ferreri AJ, Blay JY, Reni M, Pasini F, Gubkin A, Tirelli U, Calderoni A, Zucca E, Cortelazzo S, Chassagne C, Tinguel M, Borisch B, Berger F, Ponzoni M, Cavalli F; International Extranodal Lymphoma Study Group (IELSG) (2002) Relevance of intraocular involvement in the management of primary central nervous system lymphomas. Ann Oncol 13:531–538CrossRefPubMed
15.
Ferreri AJ, Blay JY, Reni M, Pasini F, Spina M, Ambrosetti A, Calderoni A, Rossi A, Vavassori V, Conconi A, Devizzi L, Berger F, Ponzoni M, Borisch B, Tinguely M, Cerati M, Milani M, Orvieto E, Sanchez J, Chevreau C, Dell'Oro S, Zucca E, Cavalli F (2003) Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group Experience. J Clin Oncol 21:266–272CrossRefPubMed
16.
Fine HA, Mayer RJ (1993) Primary central nervous system lymphoma. Ann Intern Med 119:1093–1104PubMed
17.
Hoffman PM, McKelvie P, Hall AJ, Stawell RJ, Santamaria JD (2003) Intraocular lymphoma: a series of 14 patients with clinicopathological features and treatment outcomes. Eye 17:513–521CrossRefPubMed
18.
Hormigo A, Abrey L, Heinemann MH, DeAngelis LM (2004) Ocular presentation of primary central nervous system lymphoma: diagnosis and treatment. Br J Haematol 126:202–208CrossRefPubMed
19.
Jaffe ES, Harris NL, Stein H, Vardiman JW (2001) World Health Organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. IARC Press, Lyon
20.
Jahnke K, Bechrakis NE, Coupland SE, Schmittel A, Foerster MH, Fischer L, Thiel E, Korfel A (2004) Treatment of primary intraocular lymphoma with oral trofosfamide: report of two cases and review of the literature. Graefe Arch Clin Exp Ophthalmol 242:771–776CrossRef
21.
Mead GM, Bleehen NM, Gregor A, Bullimore J, Shirley D, Rampling RP, Trevor J, Glaser MG, Lantos P, Ironside JW, Moss TH, Brada M, Whaley JB, Stenning SP (2000) A medical research council randomized trial in patients with primary cerebral non-Hodgkin lymphoma: cerebral radiotherapy with and without cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy. Cancer 89:1359–1370CrossRefPubMed
22.
O'Neill BP, Wang CH, O'Fallon JR, Colgan JD, Earle JD, Krigel RL, Brown LD, McGinnis WL (1999) Primary central nervous system non-Hodgkin's lymphoma (PCNSL): survival advantages with combined initial therapy? A final report of the North Central Cancer Treatment Group (NCCTG) Study 86-72-52. Int J Radiat Oncol Biol Phys 43:559–563CrossRefPubMed
23.
Peterson K, Gordon KB, Heinemann MH, DeAngelis L (1993) The clinical spectrum of ocular lymphoma. Cancer 72:843–849PubMedCrossRef
24.
Rothova A, Ooijman F, Kerkhoff F, Van Der Lelij A, Lokhorst HM (2001) Uveitis masquerade syndromes. Ophthalmology 108:386–399CrossRefPubMed
25.
Schultz C, Scott C, Sherman W, Donahue B, Fields J, Murray K, Fisher B, Abrams R, Meis-Kindblom J (1996) Preirradiation chemotherapy with cyclophosphamide, doxorubicin, vincristine, and dexamethasone for primary CNS lymphomas: initial report of radiation therapy oncology group protocol 88-06. J Clin Oncol 14:556–564PubMed
26.
Smith JR, Rosenbaum JT, Wilson DJ, Doolittle ND, Siegal T, Neuwelt EA, Pe'er J (2002) Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement. Ophthalmology 109:1709–1716CrossRefPubMed
27.
Soussain C, Suzan F, Hoang-Xuan K, Cassoux N, Levy V, Azar N, Belanger C, Achour E, Ribrag V, Gerber S, Delattre JY, Leblond V (2001) Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J Clin Oncol 19:742–749PubMed
28.
Strauchen JA, Dalton J, Friedman AH (1989) Chemotherapy in the management of intraocular lymphoma. Cancer 63:1918–1921PubMedCrossRef
29.
Wagner A, Hempel G, Boos J (1997) Trofosfamide: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the oral treatment of cancer. Anticancer Drugs 8:419–431PubMedCrossRef
30.
Whitcup SM, de Smet MD, Rubin BI, Palestine AG, Martin DF, Burnier M Jr, Chan CC, Nussenblatt RB (1993) Intraocular lymphoma. Clinical and histopathologic diagnosis. Ophthalmology 100:1399–1406PubMed
31.
Yule SM, Price L, Pearson AD, Boddy AV (1997) Cyclophosphamide and ifosfamide metabolites in the cerebrospinal fluid of children. Clin Cancer Res 3:1985–1992PubMed
32.
Zaldivar RA, Martin DF, Holden JT, Grossniklaus HE (2004) Primary intraocular lymphoma: clinical, cytologic, and flow cytometric analysis. Ophthalmology 111:1762–1767CrossRefPubMed
Metadata
Title
Intraocular lymphoma 2000–2005: results of a retrospective multicentre trial
Authors
Kristoph Jahnke
Agnieszka Korfel
Julia Komm
Nikolaos E. Bechrakis
Harald Stein
Eckhard Thiel
Sarah E. Coupland
Publication date
01-06-2006
Publisher
Springer-Verlag
Published in
Graefe's Archive for Clinical and Experimental Ophthalmology / Issue 6/2006
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI
https://doi.org/10.1007/s00417-005-0138-9

Other articles of this Issue 6/2006

Graefe's Archive for Clinical and Experimental Ophthalmology 6/2006 Go to the issue

Laboratory investigation

Keratoepithelin in secondary corneal amyloidosis

Book Review

Gerald L. Mandell, John E. Bennett, Raphael Dolin (eds): Principles and Practice of Infectious Diseases, 6th edn

Laboratory Investigation

Human retinal epithelium produces and responds to placenta growth factor

Case Report

Acute choroidal closure caused by hemodialysis accident in an amyloidosic patient

Clinical Investigation

Increased nitric oxide (NO) pathway metabolites in the vitreous fluid of patients with rhegmatogenous retinal detachment or diabetic traction retinal detachment

Clinical Investigation

Conversion of intermittent exotropia types subsequent to part-time occlusion therapy and its sustainability